Abstract
Get full access to this article
View all access options for this article.
References
1.
“A Phase III Study of Pembrolizumab + Epacadostat or Placebo in Subjects with Unresectable or Metastatic Melanoma ” (Keynote-252 / ECHO-301) . https://clinicaltrials.gov/ct2/show/NCT02752074.
2.
“Safety Study of Chimeric Antigen Receptor Modified T-Cells Targeting NKG2D-Ligands ,” https://clinicaltrials.gov/ct2/show/NCT02203825.
3.
“A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) ,” https://clinicaltrials.gov/ct2/show/NCT03018405.
4.
Agersborg
S.
et al. “PD-L1 Expression Correlates with TP53 Gene Mutation Status in Lung Cancer but Not in Colorectal Cancer ,” https://neogenomics.com/Portals/0/pdf/Pub-Abstracts/PD-L1-Abstract-Poster_ASCO-2016_Final.pdf.
5.
Albitar
M.
, “Comparison of PD-L1 Companion, Complementary and Laboratory Developed Tests with Molecular Profiling” (webinar), https://neogenomics.wistia.com/medias/ojprfd9zpc.
6.
Ramanathan
R.K.
et al. , “Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study ,”
Clin. Cancer Res.
, 23 (14 ): 3638 –3648 , (July 15 , 2017 ), http://clincancerres.aacrjournals.org/content/23/14/3638.long.
7.
Korn
R.L.
et al. “18F-FDG PET/CT Response in a Phase I/II Trial of Nab-Paclitaxel Plus Gemcitabine for Advanced Pancreatic Cancer ,”
Cancer Imaging
2017 17: 23. https://cancerimagingjournal.biomedcentral.com/articles/10.1186/s40644-017-0125-5.
8.
Raghunand
N.
et al. , “Magnetic Resonance Imaging of RRx-001 Pharmacodynamics in Preclinical Tumors ,”
Oncotarget
, 8 (60 ): 102511 –102520 (June 12 , 2017 ), https://www.ncbi.nlm.nih.gov/pubmed/29254266.